Skip to content
10-Q

Quarterly Report

TENAX THERAPEUTICS, INC. TENX

0000950170-25-071395

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 4.15M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $111.4M
Current Liabilities Q1 2025 · Mar 31, 2025 $2.77M
Current Liabilities Q1 2025 · Dec 31, 2024 $4.69M
Total Liabilities Q1 2025 · Mar 31, 2025 $2.77M
Total Liabilities Q1 2025 · Dec 31, 2024 $4.69M
Current Assets Q1 2025 · Mar 31, 2025 $112.06M
Current Assets Q1 2025 · Dec 31, 2024 $96.69M
Total Assets Q1 2025 · Mar 31, 2025 $112.06M
Total Assets Q1 2025 · Dec 31, 2024 $96.69M
Revenue Q1 2025 · Mar 31, 2025 $0
Shares Diluted Q1 2025 · Mar 31, 2024 1.22M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$5.17M
Stockholders Equity restated Q1 2025 · Mar 31, 2024 $12.43M
Stockholders Equity restated Q1 2025 · Dec 31, 2023 $8.1M
Eps Diluted Q1 2025 · Mar 31, 2024 −$3.12
Eps Basic Q1 2025 · Mar 31, 2024 −$3.12
Rd Expense restated Q1 2025 · Mar 31, 2024 $2.68M
Net Income restated Q1 2025 · Mar 31, 2024 −$3.8M
Operating Income restated Q1 2025 · Mar 31, 2024 −$3.91M